Navigation Links
Pediatric Asthma Programs Featuring PARI Pharma's eFlow Acquired by AstraZeneca
Date:9/24/2007

MONTEREY, Calif., Sept. 24 /PRNewswire/ -- Today, the rights to Verus Pharmaceuticals' pediatric asthma development programs that utilize PARI's eFlow electronic nebulizer for aerosol delivery were acquired by AstraZeneca. Following Gilead Sciences' acquisition of Corus Pharma in August 2006, this is the second major pharmaceutical acquisition where a licensed eFlow is featured prominently in the development pipeline.

Included in the AstraZeneca acquisition are the North American rights to a Captisol(R) enabled budesonide solution (controller medication), a proprietary short-acting beta-agonist solution (rescue medication), a customized version of eFlow(R) (novel aerosol delivery device) for use with both products, and other intellectual property and related assets from Verus.

This is the second acquisition by a large pharmaceutical company where purchases have included the licensing of PARI's eFlow in the development program. In August 2006, Gilead Sciences acquired Corus Pharma for $365 million. In December 2006, Gilead Sciences released positive preliminary results of their Phase III trial on AIR-CF2, a potential treatment for cystic fibrosis patients that have pulmonary Pseudomonas aeruginosa. These positive preliminary results were the first Phase III clinical trial results highlighting the optimization of drug to device and device to drug with PARI's eFlow, an advanced electronic nebulizer.

About eFlow

eFlow uses a vibrating, perforated membrane that enables extremely efficient aerosolization of liquid medications. Compared to other nebulizer systems, eFlow can produce aerosols with a very high density of active drug, a precisely defined droplet size, and a high proportion of respirable droplets delivered in the shortest possible amount of time. Combined with its silent mode of operation, small size (it fits in the palm of your hand), light weight, and battery use, eFlow helps reduce the burden of taking daily-inhaled treatments.

Due to its efficiency, eFlow is licensed to pharmaceutical companies during drug development and for later commercialization so that drug and device are optimized together for the final product. This customization is currently being utilized in the development of new and improved treatments for cystic fibrosis, asthma, and chronic obstructive pulmonary disease (COPD).

About PARI Pharma

PARI Pharma develops aerosol delivery devices and inhaled therapies. Based on PARI's 100-year history working with aerosols, PARI Pharma specializes in treatments for pulmonary and nasal administration optimized to advanced delivery platforms, such as eFlow.

Focusing on comprehensive inhalation therapy development, including optimized nebulizer formulations, analytics, and aerosol characterization, PARI Pharma has several clinical development programs ongoing, either partnered or proprietary. PARI Pharma, a PARI Medical Holding company, is located in Munich, Germany, with a major presence in the United States. Online at http://www.paripharma.com


'/>"/>
SOURCE PARI Pharma
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. High-throughput gene expression analysis to screen for anti-asthma drugs
2. Bio-Plex Cytokine Immunoassays and ELISA: Comparison of Two Methodologies in Testing Samples From Asthmatic and Healthy Children, Rev A
3. Are guest worker programs causing backlash amid IT downsizing?
4. FDA programs encourage and expedite drug development and approval
5. SecurePipe acquires mailMax programs
6. British come to Madison; UW starts stem-cell programs
7. Stem-cell study grows too big for one department; UW builds collaborative programs
8. Inacom targets diversity programs as Milwaukee expansion drives growth
9. Interview: New commerce secretary wants to keep momentum on jobs and business programs
10. Experts share advice for Wisconsin entrepreneur programs
11. An analysis of Wisconsins new venture capital and early stage finance programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... ... April 20, 2017 , ... As part of ... explore challenging patient cases when screening for direct oral anticoagulant. When patients taking ... need for bridging parental anticoagulation especially for those at high risk of thrombosis ...
(Date:4/20/2017)...  Eli Lilly and Company (NYSE: LLY ... the prevention of migraine at the American Academy of ... 22-28, 2017, in Boston . ... including safety and patient outcomes data for galcanezumab in ... in monthly migraine headache days among patients with episodic ...
(Date:4/20/2017)... ... April 20, 2017 , ... ... and clinical research community’s growing body of knowledge during its Eighth Annual ... Theatre and the adjacent Darling Atrium. During the event, undergraduates, graduate students, and ...
(Date:4/20/2017)... 20, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: ... the International Liver Congress ("ILC") 2017 of the European Association ... Amsterdam on the positive effects of PBI-4050 on ... obesity and metabolic syndrome. ... According to Dr. Lyne Gagnon, Vice-President of R&D Pre-clinical of ...
Breaking Biology Technology:
(Date:4/11/2017)... Apr. 11, 2017 Research and Markets has ... report to their offering. ... The global eye tracking market to grow at a CAGR of ... Eye Tracking Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
(Date:4/5/2017)... Allen Institute for Cell Science today announces the launch ... dynamic digital window into the human cell. The website ... deep learning to create predictive models of cell organization, ... suite of powerful tools. The Allen Cell Explorer will ... resources created and shared by the Allen Institute for ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
Breaking Biology News(10 mins):